You are here
Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer
Shitara K, Muro K, Shimada Y, Hironaka S, Sugimoto N, Komatsu Y, et al.Gastric Cancer. 2015 Oct 28. [Epub ahead of print]
Impact of age on the feasibility and efficacy of neoadjuvant chemotherapy in patients with locally advanced oesophagogastric cancer
Lorenzen Sylvie, Spoerl Silvia, Al-Batran Salah-Eddin, Feith Markus, Lordick Florian, Thuss-Patience Peter, Haller Bernhard, Angele Martin, Novotny Alexander
European Journal of Cancer, Volume 51, Issue 14, September 2015, Pages 1918 - 1926
Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS)
Ryu MH, Baba E, Lee KH, Park YI, Boku N, Hyodo I,et al.Ann Oncol. 2015 Oct;26(10):2097-101
NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors
Schulz C, Kullmann F, Kunzmann V, Fuchs M, Geissler M, Vehling-Kaiser U, et al.Int J Cancer. 2015 Aug 1;137(3):678-85.
Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium
Shah MA, Janjigian YY, Stoller R, Shibata S, Kemeny M, Krishnamurthi S, et al.J Clin Oncol. 2015 Oct 5. [Epub ahead of print]
TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG).
Leong T, Smithers BM, Michael M, Gebski V, Boussioutas A, Miller D, et al.BMC Cancer 2015 Jul 21;15:532.